(Q37032564)

22 December 2017

review article

1 reference

title

Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults (English)

1 reference

22 December 2017

Katherine A Lyseng-Williamson

1 reference

series ordinal

4

object named as

Katherine A Lyseng-Williamson

1 reference

22 December 2017

5

Gillian M Keating

1 reference

22 December 2017

1

Kate McKeage

1 reference

22 December 2017

author name string

Stephanie K A Blick

series ordinal

2

1 reference

22 December 2017

Jamie D Croxtall

series ordinal

3

1 reference

22 December 2017

publication date

1 January 2008

1 reference

22 December 2017

published in

Drugs

1 reference

22 December 2017

volume

68

1 reference

22 December 2017

issue

11

1 reference

22 December 2017

page(s)

1571-1607

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200868110-00009

exact match

0 references

cites work

Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868110-00009

Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868110-00009

Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study

21 January 2018

1 reference

12 December 2020

One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study.

1 reference

12 December 2020

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

1 reference

12 December 2020

Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease

1 reference

12 December 2020

Drug interactions between proton pump inhibitors and antiretroviral drugs.

1 reference

12 December 2020

Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

1 reference

12 December 2020

Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus

1 reference

12 December 2020

A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication

1 reference

12 December 2020

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

12 December 2020

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

1 reference

12 December 2020

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

1 reference

12 December 2020

Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis

1 reference

12 December 2020

Medical management of gastroesophageal reflux disease

1 reference

12 December 2020

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease

1 reference

12 December 2020

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study

1 reference

12 December 2020

Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial

1 reference

12 December 2020

One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection

1 reference

12 December 2020

Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers

1 reference

12 December 2020

Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams

1 reference

12 December 2020

A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers

1 reference

12 December 2020

Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.

1 reference

12 December 2020

The burden of illness of gastro-oesophageal reflux disease: impact on work productivity.

1 reference

12 December 2020

Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups

1 reference

12 December 2020

Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms

1 reference

12 December 2020

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials

1 reference

12 December 2020

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

1 reference

12 December 2020

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

1 reference

12 December 2020

The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole

1 reference

12 December 2020

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

1 reference

12 December 2020

Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough

1 reference

12 December 2020

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

1 reference

12 December 2020

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

1 reference

12 December 2020

One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease

1 reference

12 December 2020

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

1 reference

12 December 2020

On-demand therapy for gastroesophageal reflux disease

1 reference

12 December 2020

Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole

1 reference

12 December 2020

Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse

1 reference

12 December 2020

Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment

1 reference

12 December 2020

Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole

1 reference

12 December 2020

Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?

1 reference

12 December 2020

High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection

1 reference

12 December 2020

Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial

1 reference

12 December 2020

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

1 reference

12 December 2020

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

1 reference

12 December 2020

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

12 December 2020

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects

1 reference

12 December 2020

Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole

1 reference

12 December 2020

Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study

1 reference

12 December 2020

A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis

1 reference

12 December 2020

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

12 December 2020

Effects of 6-12 months of esomeprazole treatment on the gastric mucosa

1 reference

12 December 2020

One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease

1 reference

12 December 2020

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

12 December 2020

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

1 reference

12 December 2020

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

1 reference

12 December 2020

Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis

1 reference

12 December 2020

Pharmacokinetics of [14C]omeprazole in patients with impaired renal function

1 reference

12 December 2020

Guidelines for the management of dyspepsia

1 reference

12 December 2020

Review article: acid-related disease--what are the unmet clinical needs?

1 reference

12 December 2020

Drug interactions between HIV protease inhibitors and acid-reducing agents.

1 reference

12 December 2020

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

12 December 2020

Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn

1 reference

12 December 2020

Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH.

1 reference

12 December 2020

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

1 reference

12 December 2020

Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial

1 reference

12 December 2020

The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome

1 reference

12 December 2020

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

12 December 2020

Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

1 reference

12 December 2020

Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial

1 reference

12 December 2020

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

1 reference

12 December 2020

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

12 December 2020

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.

1 reference

12 December 2020

Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori

1 reference

12 December 2020

Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers

1 reference

12 December 2020

The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life.

1 reference

12 December 2020

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

1 reference

12 December 2020

Epidemiology of gastro-oesophageal reflux disease: a systematic review

1 reference

12 December 2020

Pharmacokinetic study of esomeprazole in the elderly

1 reference

12 December 2020

A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease

1 reference

12 December 2020

40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms

1 reference

12 December 2020

Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care

1 reference

12 December 2020

A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers

1 reference

12 December 2020

Esomeprazole: in gastroesophageal reflux disease in children and adolescents

1 reference

12 December 2020

Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole

1 reference

12 December 2020

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease

1 reference

12 December 2020

The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus

1 reference

12 December 2020

Helicobacter pylori treatment: a practical approach

1 reference

12 December 2020

Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers

1 reference

12 December 2020

Medical therapy of gastroesophageal reflux disease

1 reference

12 December 2020

An update on the available treatments for non-erosive reflux disease

1 reference

12 December 2020

Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.

1 reference

12 December 2020

Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.

1 reference

12 December 2020

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease.

1 reference

12 December 2020

Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients

1 reference

12 December 2020

Nonsteroidal antiinflammatory drugs and the gastrointestinal tract

1 reference

12 December 2020

Effects of esomeprazole magnesium on nonsteroidal anti-inflammatory drug gastropathy

1 reference

12 December 2020

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data

1 reference

12 December 2020

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

1 reference

12 December 2020

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

1 reference

12 December 2020

Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general med

1 reference

12 December 2020

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

1 reference

12 December 2020

Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study

1 reference

12 December 2020

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

1 reference

12 December 2020

Esomeprazole: a review of its use in the management of acid-related disorders

1 reference

12 December 2020

Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?

1 reference

12 December 2020

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

1 reference

12 December 2020

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

1 reference

12 December 2020

Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.

1 reference

12 December 2020

A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis

1 reference

12 December 2020

One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients

1 reference

12 December 2020

Pharmacokinetic study of esomeprazole in patients with hepatic impairment

1 reference

12 December 2020

The impact of gastroesophageal reflux disease on health-related quality of life.

1 reference

12 December 2020

Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general

1 reference

12 December 2020

The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.

1 reference

12 December 2020

Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis

1 reference

12 December 2020

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

1 reference

12 December 2020

Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers

1 reference

12 December 2020

Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers

1 reference

12 December 2020

Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing

1 reference

12 December 2020

Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

1 reference

12 December 2020

The choice of proton pump inhibitor: does it matter?

1 reference

12 December 2020

Acid control with esomeprazole and lansoprazole: a comparative dose-response study

1 reference

12 December 2020

Long-term proton pump inhibitor therapy and risk of hip fracture

1 reference

12 December 2020

Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

1 reference

12 December 2020

10.2165/00003495-200868110-00009

Identifiers

DOI

1 reference

22 December 2017

Dimensions Publication ID

1036335122

0 references

1 reference

22 December 2017